Transforming Alkermes into a Global Biopharmaceutical Company Harvard Case Solution & Analysis

facebooktwittergoogle_plusmail

In the summer of 2011, Jim Frates, CFO of Alkermes faced choices about the best way to invest the assets of Dublin, Ireland-based Elan Drug Technologies (EDT) – a deal which was anticipated to narrow the fall.

The case describes the history of Alkermes, provides information about the planned combiner, and explains the financing options. The case gives pupils the chance to assess the attractiveness of the merger to assess the function CFOs play in biopharmaceutical businesses, and to choose a funding option.

This is just an excerpt. This case is about FINANCE & ACCOUNTING

PUBLICATION DATE: May 28, 2015 PRODUCT #: 215079-PDF-ENG

 

How We Work?
Just email us your case materials and instructions to order@thecasesolutions.com and confirm your order by making the payment here

Other Similar Case Solutions like

Transforming Alkermes into a Global Biopharmaceutical Company